ozanimod hydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
ozanimod hydrochloride: clinical details
Prescribing considerations
- Initiate under a clinician experienced in managing multiple sclerosis or ulcerative colitis.
- Review cardiac history, infection, previous immunosuppression, vaccination status, liver and respiratory disease, and skin-cancer risk.
- Check varicella immunity and arrange vaccination before treatment when indicated.
- Diabetes, uveitis or retinal disease require ophthalmological assessment.
- Consider cardiology advice and supervised first exposure for specified bradycardia or conduction risks.
Contraindications and cautions
- Hypersensitivity to ozanimod or an excipient
- Immunodeficiency predisposing to systemic opportunistic infection
- Recent myocardial infarction, unstable angina, stroke, transient ischaemic attack or specified severe heart failure
- Second-degree type II or third-degree atrioventricular block, or sick sinus syndrome, without a functioning pacemaker
- Severe active or chronic infection, including active hepatitis or tuberculosis
- Active malignancy
- Severe hepatic impairment
- Pregnancy or childbearing potential without effective contraception
Monitoring
- ECG before treatment; targeted heart-rate, blood-pressure and ECG observation where cardiac risk factors are present.
- Baseline and periodic full blood count, including lymphocytes.
- Baseline and regular liver transaminases and bilirubin.
- Regular blood-pressure assessment.
- Monitor for infection during treatment and for three months after stopping.
- Urgently assess new neurological, psychiatric or visual symptoms for PML, PRES or macular oedema.
- Continue surveillance for suspicious skin lesions and advise ultraviolet protection.
Clinical pharmacology
Ozanimod is a selective S1P1 and S1P5 receptor modulator. Functional antagonism of S1P1 limits lymphocyte egress from lymphoid tissue. It is extensively metabolised, and two long-lived active metabolites account for most circulating active exposure.
Formulation and product differences
- Available as colour-coded hard capsules in an initiation pack and separate maintenance packs.
- Capsules contain gelatin and differ in shell colouring; all are effectively sodium-free and potassium-free.
- Store below 25°C in the original blister packaging.
ozanimod hydrochloride preparations and strengths
Capsule
Route: Oral
Strengths: 0.23 mg, 0.92 mg
ozanimod hydrochloride interactions
Check all prescribed, over-the-counter and complementary products before treatment.
Anticancer, immunomodulatory or non-corticosteroid immunosuppressive treatments
Concurrent use should be avoided because immune suppression and infection risk may be additive.
Live attenuated vaccines
Avoid during treatment and for three months afterwards; other vaccines may be less effective.
Monoamine oxidase inhibitors, including phenelzine or selegiline
Combination is not recommended because it may alter exposure to active metabolites and reduce clinical response.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.